<DOC>
	<DOCNO>NCT00510874</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response two-doses GSK Biologicals ' candidate influenza vaccine GSK 1557484A without adjuvant adult . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Study Evaluate Safety Immune Response Two-Doses Candidate Influenza Vaccine GSK 1557484A Adults</brief_title>
	<detailed_description>The study five core arm stratification base site age . In addition , 4 possible contingent group 2 study base analysis concern immunogenicity performance Day 42 core group .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female adult 18 64 year age time first vaccination , inclusive . Good general health assess medical history physical examination . Access consistent mean telephone contact Written inform consent obtain subject . Comprehension study requirement , express availability require study period , ability attend schedule visit . Subjects investigator believe comply requirement protocol enrol study . Presence significant acute chronic , uncontrolled medical psychiatric illness Presence evidence substance abuse neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Blood pressure abnormality Diagnosed cancer , treatment cancer , within 3 year . Persons history cancer diseasefree without treatment 3 year eligible . Persons history histologicallyconfirmed basal cell carcinoma skin successfully treat local excision except may enroll , histologic type skin cancer exclusionary . Women diseasefree 3 year treatment breast cancer receive longterm prophylactic tamoxifen except may enroll . Presence oral temperature ≥ 37.8º C , acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt cytotoxic immunosuppressive drug within 6 month study enrollment . Any significant disorder coagulation treatment Coumadin derivatives heparin . Administration noninfluenza vaccine within 30 day study enrollment study period . Use investigational nonregistered product ( drug vaccine ) plan participation another investigational study within 30 day prior study enrollment , study period . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any known suspected allergy constituent influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( ßhCG ) test result prior dose Study Days 0 21 . Lactating nursing . Women child bear potential lack history reliable contraceptive practice . Known receipt analgesic antipyretic medication day treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>GSK 1557484A vaccine</keyword>
</DOC>